Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 586 across all filing types
Latest filing 2021-11-10 Regulatory Filings
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing by Sutro Biopharma, Inc. which serves as a notice that the company has issued a press release regarding financial results and an updated corporate presentation. Per the 'Menu vs Meal' rule, since this is a short regulatory filing (Form 8-K) that announces the availability of other documents (the press release and presentation) rather than being the financial report or presentation itself, it falls under the Regulatory Filings category.
2021-11-10 English
10-Q
Interim / Quarterly Report Q3 2021
2021-11-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or agreements. The text describes the entry into a material definitive agreement (an option agreement with BioNova Pharmaceuticals) including financial terms and rights. It is not a full financial report, earnings release, or management discussion, but rather an announcement of a significant contract. The document length is 4104 characters, which is relatively short and typical for an 8-K filing. The content fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a material agreement and does not fit other more specific categories like Capital/Financing Update or M&A Activity since it is an option agreement rather than a merger or financing event. Therefore, the best classification is Regulatory Filings (RNS).
2021-10-12 English
8-K_MERCKAMEND
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an extension of a research term in a collaboration agreement and associated payments, which is a material event but not a full financial report. The document does not contain comprehensive financial statements or detailed financial analysis, so it is not an Annual Report (10-K) or Interim Report (IR). It is not an earnings release or management discussion. The document is a regulatory announcement of a material event, fitting the category of Regulatory Filings (RNS). The length is about 5,313 characters, which is typical for an 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-09-30 English
FORM 4 SUBMISSION
Director's Dealing
2021-09-29 English
FORM 4 SUBMISSION
Director's Dealing
2021-09-29 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.